TOBIRA THERAPEUTICS INC

Strumento inattivo

Azioni Tobira Therapeutics Inc

Azioni

US88883P1012

Biotecnologia

Prezzo di chiusura Nasdaq Altri mercati azionari
- ^USD	-

su tutti i nostri abbonamenti*

Approfitta dell'offerta

*Vedi le condizioni sul sito

Notizie in altre lingue su Tobira Therapeutics Inc

TOBIRA fait gagner plus de 40 000 euros à un investisseur !	26/10/16
Tobira Therapeutics : Announces Late-Breaking Oral Presentation of CENTAUR Phase 2b Trial Results at the American Academy for the Study of Liver Diseases Annual Meeting	20/10/16
Tobira Therapeutics : Announces Presentations Related to Cenicriviroc’s Development Program in NASH at the American Academy for the Study of Liver Diseases Annual Meeting	03/10/16
TBRA Brower Piven Commences An Investigation Into The Proposed Sale Of Tobira Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information	21/09/16
Tobira Therapeutics : Allergan to Acquire Tobira Therapeutics Expanding Global GI R&D Pipeline and Taking a Leading R&D Position in NASH	20/09/16

Dirigenti e Amministratori - Tobira Therapeutics Inc

Dirigenti	Titolo	Età	Da
Robert Michael CEO	Chief Executive Officer	53	-
Scott Reents DFI	Director of Finance/CFO	57	-
Jennifer M. Lagunas SEC	Corporate Secretary	-	-

Profilo Società

Settore

Altre informazioni sulla società

Settore Farmaci bioterapeutici

	Variaz. 1 gen.	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+9,58%	115 Mrd
REGENERON PHARMACEUTICALS, INC.	+12,41%	106 Mrd
ARGENX SE	-2,59%	21,96 Mrd
BIONTECH SE	-12,38%	21,87 Mrd
GENMAB A/S	-5,29%	19,21 Mrd
BEIGENE, LTD.	-3,35%	18,08 Mrd
WUXI APPTEC CO., LTD.	-38,57%	17,71 Mrd
NEUROCRINE BIOSCIENCES, INC.	+7,51%	14,32 Mrd
SAREPTA THERAPEUTICS, INC.	+35,67%	12,42 Mrd

Farmaci bioterapeutici

-40% Offerta a tempo limitato: i nostri abbonamenti ti guidano verso i migliori investimenti di domani.

APPROFITTANE ORA